biontech® + turkovac  (BioNTech)

Journal: Frontiers in Medicine

Article Title: Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months

doi: 10.3389/fmed.2025.1524393

Figure Lengend Snippet: Memory B cell responses induced by TURKOVAC vaccination. The absolute number of spike-specific memory B cells (A) , IgM+ (B) , and IgG+ (C) B cells per 5 × 10 5 PBMCs before and after vaccinations. Red, green, and blue indicate all volunteers, volunteers with two doses of vaccination, and volunteers with three doses of vaccination, respectively. Values are expressed as arithmetic mean and standard deviation; p † indicates the significance for between-group comparisons; p ‡ indicates the significance for within-group comparisons. All baseline values were one (1.00) before the transformation. Standard deviation statistic was not calculated, thus this time point was not included in within-group comparisons. Since shifted logarithmic transformation (log(x + 1)) was applied, this quantity, as well as the mean statistic, is computed as 0.30. Significant p values are shown in bold.

Article Snippet: Comparison of our results with those of BioNTech and other vaccine platforms indicates that immunization with TURKOVAC is successfully able to induce the expansion of spike-specific B cell clones and memory B cells, which may persist for up to 8 months post-vaccination.

Techniques: Standard Deviation, Transformation Assay

Journal: Anatolian Journal of Cardiology

Article Title: Comparison of the Effects of Recent Coronavirus 2019 Infection and Vaccination on the Prognosis of Acute Coronary Syndrome: A Retrospective Study Conducted in a Single Center in Türkiye

doi: 10.14744/AnatolJCardiol.2024.4372

Figure Lengend Snippet: Study Group Descriptives

Article Snippet: Biontech + Turkovac , 9 (0.68%) , 0 (0.00%)*.

Techniques: Filtration

Journal: Anatolian Journal of Cardiology

Article Title: Comparison of the Effects of Recent Coronavirus 2019 Infection and Vaccination on the Prognosis of Acute Coronary Syndrome: A Retrospective Study Conducted in a Single Center in Türkiye

doi: 10.14744/AnatolJCardiol.2024.4372

Figure Lengend Snippet: Summary of Variables with Regard to Major Adverse Cardiac Event

Article Snippet: Biontech + Turkovac , 9 (0.68%) , 0 (0.00%)*.

Techniques: Filtration

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Patient distribution according to age and sex quotas [ 10 ].

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques:

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Characteristics of the study participants.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques:

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: The time between the second dose and the booster dose in the TURKOVAC and CoronaVac vaccine arms.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques:

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Neutralizing antibody positivity against the Wuhan variant in TURKOVAC and CoronaVac vaccine arms at the threshold value of ≥1/6.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques: Variant Assay

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Neutralizing antibody positivity against the Wuhan variant in the TURKOVAC and CoronaVac vaccine arms at the threshold value of ≥1/6: ( a ) in females; ( b ) in males.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques: Variant Assay

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Neutralizing antibody positivity against the Wuhan variant in the TURKOVAC and CoronaVac vaccine arms at the threshold value of 1/6 in the ( a ) 18–29 years age group; ( b ) 30–39 years age group; ( c ) 40–49 years age group; and ( d ) 50–60 years age group.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques: Variant Assay

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Neutralizing antibody positivity against the Delta variant in the TURKOVAC and CoronaVac vaccine arms at the threshold value of ≥1/6.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques: Variant Assay

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Neutralizing antibody positivity against the Delta variant in the TURKOVAC and CoronaVac vaccine arms at the threshold value of ≥1/6: ( a ) in females; ( b ) in males.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques: Variant Assay

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Neutralizing antibody positivity against the Delta variant in the TURKOVAC and CoronaVac vaccine arms at the threshold value of ≥1/6 in the ( a ) 18–29 years age group; ( b ) 30–39 years age group; ( c ) 40–49 years age group; and ( d ) 50–60 years age group.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques: Variant Assay

Journal: Vaccines

Article Title: Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

doi: 10.3390/vaccines11071234

Figure Lengend Snippet: Distribution of participants with a 4-fold increase in anti-spike IgG antibody titers according to sex.

Article Snippet: TURKOVAC vaccine, which was manufactured by Kocak Farma (Koçak Farma Production Facilities, Tekirdag, Türkiye) using hCoV-19 strain (hCoV-19/Turkiye/ERAGEM-001/2020 strain, GenBank accession number; MT327745.1 and GISAID; EPI_ISL_424366), contains 600 SU (3 μg) of SARS-CoV-2 antigen as the inactivated active ingredient and Alum Gel (10% AlOH–InvivoGen, San Diego, CA, USA) of 0.50 mg as adjuvant in a 0.5 mL milky-white suspension without any preservatives or stabilizers.

Techniques: